These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 24884503)

  • 1. Large-scale label-free comparative proteomics analysis of polo-like kinase 1 inhibition via the small-molecule inhibitor BI 6727 (Volasertib) in BRAF(V600E) mutant melanoma cells.
    Cholewa BD; Pellitteri-Hahn MC; Scarlett CO; Ahmad N
    J Proteome Res; 2014 Nov; 13(11):5041-50. PubMed ID: 24884503
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Small molecule inhibition of polo-like kinase 1 by volasertib (BI 6727) causes significant melanoma growth delay and regression in vivo.
    Cholewa BD; Ndiaye MA; Huang W; Liu X; Ahmad N
    Cancer Lett; 2017 Jan; 385():179-187. PubMed ID: 27793694
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro study of the Polo-like kinase 1 inhibitor volasertib in non-small-cell lung cancer reveals a role for the tumor suppressor p53.
    Van den Bossche J; Deben C; De Pauw I; Lambrechts H; Hermans C; Deschoolmeester V; Jacobs J; Specenier P; Pauwels P; Vermorken JB; Peeters M; Lardon F; Wouters A
    Mol Oncol; 2019 May; 13(5):1196-1213. PubMed ID: 30859681
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacological inhibition of Polo-like kinase 1 (PLK1) by BI-2536 decreases the viability and survival of hamartin and tuberin deficient cells via induction of apoptosis and attenuation of autophagy.
    Valianou M; Cox AM; Pichette B; Hartley S; Paladhi UR; Astrinidis A
    Cell Cycle; 2015; 14(3):399-407. PubMed ID: 25565629
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The small-molecule inhibitor BI 2536 reveals novel insights into mitotic roles of polo-like kinase 1.
    Lénárt P; Petronczki M; Steegmaier M; Di Fiore B; Lipp JJ; Hoffmann M; Rettig WJ; Kraut N; Peters JM
    Curr Biol; 2007 Feb; 17(4):304-15. PubMed ID: 17291761
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proteasome activation is critical for cell death induced by inhibitors of polo-like kinase 1 (PLK1) in multiple cancers.
    Wang Y; Wang G; Xiang W; Liu X; Jiang M; Hu J
    Eur J Pharmacol; 2024 Jun; 972():176558. PubMed ID: 38614382
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro PLK1 inhibition by BI 2536 decreases proliferation and induces cell-cycle arrest in melanoma cells.
    de Oliveira JC; Brassesco MS; Pezuk JA; Morales AG; Valera ET; Montaldi AP; Sakamoto-Hojo ET; Scrideli CA; Tone LG
    J Drugs Dermatol; 2012 May; 11(5):587-92. PubMed ID: 22527426
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PLK1 and NOTCH Positively Correlate in Melanoma and Their Combined Inhibition Results in Synergistic Modulations of Key Melanoma Pathways.
    Su S; Chhabra G; Ndiaye MA; Singh CK; Ye T; Huang W; Dewey CN; Setaluri V; Ahmad N
    Mol Cancer Ther; 2021 Jan; 20(1):161-172. PubMed ID: 33177155
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polo-like kinase 1 (Plk1) is expressed by cutaneous T-cell lymphomas (CTCLs), and its downregulation promotes cell cycle arrest and apoptosis.
    Nihal M; Stutz N; Schmit T; Ahmad N; Wood GS
    Cell Cycle; 2011 Apr; 10(8):1303-11. PubMed ID: 21436619
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduced efficacy of the Plk1 inhibitor BI 2536 on the progression of hepatocellular carcinoma due to low intratumoral drug levels.
    Haupenthal J; Bihrer V; Korkusuz H; Kollmar O; Schmithals C; Kriener S; Engels K; Pleli T; Benz A; Canamero M; Longerich T; Kronenberger B; Richter S; Waidmann O; Vogl TJ; Zeuzem S; Piiper A
    Neoplasia; 2012 May; 14(5):410-9. PubMed ID: 22745587
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mitotic arrest and slippage induced by pharmacological inhibition of Polo-like kinase 1.
    Raab M; Krämer A; Hehlgans S; Sanhaji M; Kurunci-Csacsko E; Dötsch C; Bug G; Ottmann O; Becker S; Pachl F; Kuster B; Strebhardt K
    Mol Oncol; 2015 Jan; 9(1):140-54. PubMed ID: 25169932
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential Cellular Effects of Plk1 Inhibitors Targeting the ATP-binding Domain or Polo-box Domain.
    Shin SB; Woo SU; Yim H
    J Cell Physiol; 2015 Dec; 230(12):3057-67. PubMed ID: 25975351
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted knockdown of polo-like kinase 1 alters metabolic regulation in melanoma.
    Gutteridge RE; Singh CK; Ndiaye MA; Ahmad N
    Cancer Lett; 2017 May; 394():13-21. PubMed ID: 28235541
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polo-like kinase 1 (PLK1) inhibition suppresses cell growth and enhances radiation sensitivity in medulloblastoma cells.
    Harris PS; Venkataraman S; Alimova I; Birks DK; Donson AM; Knipstein J; Dubuc A; Taylor MD; Handler MH; Foreman NK; Vibhakar R
    BMC Cancer; 2012 Mar; 12():80. PubMed ID: 22390279
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The polo-like kinase inhibitor BI 2536 exhibits potent activity against malignant plasma cells and represents a novel therapy in multiple myeloma.
    Stewart HJ; Kishikova L; Powell FL; Wheatley SP; Chevassut TJ
    Exp Hematol; 2011 Mar; 39(3):330-8. PubMed ID: 21184800
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantitative phospho-proteomics to investigate the polo-like kinase 1-dependent phospho-proteome.
    Grosstessner-Hain K; Hegemann B; Novatchkova M; Rameseder J; Joughin BA; Hudecz O; Roitinger E; Pichler P; Kraut N; Yaffe MB; Peters JM; Mechtler K
    Mol Cell Proteomics; 2011 Nov; 10(11):M111.008540. PubMed ID: 21857030
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of Polo-like kinase 1 inhibitors on human adipose tissue-derived mesenchymal stem cells.
    Ritter A; Friemel A; Kreis NN; Louwen F; Yuan J
    Oncotarget; 2016 Dec; 7(51):84271-84285. PubMed ID: 27713178
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polo-like kinase 1 inhibition diminishes acquired resistance to epidermal growth factor receptor inhibition in non-small cell lung cancer with T790M mutations.
    Wang Y; Singh R; Wang L; Nilsson M; Goonatilake R; Tong P; Li L; Giri U; Villalobos P; Mino B; Rodriguez-Canales J; Wistuba I; Wang J; Heymach JV; Johnson FM
    Oncotarget; 2016 Jul; 7(30):47998-48010. PubMed ID: 27384992
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of polo-like kinase 1 leads to the suppression of osteosarcoma cell growth in vitro and in vivo.
    Liu X; Choy E; Harmon D; Yang S; Yang C; Mankin H; Hornicek FJ; Duan Z
    Anticancer Drugs; 2011 Jun; 22(5):444-53. PubMed ID: 21399492
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BI_2536--targeting the mitotic kinase Polo-like kinase 1 (Plk1).
    Wäsch R; Hasskarl J; Schnerch D; Lübbert M
    Recent Results Cancer Res; 2010; 184():215-8. PubMed ID: 20072841
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.